[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:ewing-sarcoma:hla-complex":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Ewing Sarcoma","HLA Complex",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05238792","Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.959678Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT01804634","Reduced Intensity Haploidentical BMT for High Risk Solid Tumors",[20],"Phase 2","2026-08-26T02:15:50.539717Z","2026-05-05T02:43:27.448232Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07695311","EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-19T19:36:05.175768Z"]